Form 4: Phibro CEO Sells $1.89M in Stock via 10b5-1 Plan

Phibro Animal Health Corporation's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold over 41,000 shares of Class A Common Stock for approximately $1.89 million through a pre-arranged trading plan.

Summary

• Jack Bendheim, President and CEO, Director, and 10% owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 41,823 shares were sold across multiple transactions on November 7, 2025, and November 10, 2025.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• The weighted average prices for the sales ranged from $42.8554 to $46.3558 per share.
• The estimated total value of the shares sold is approximately $1.89 million.
• Following these transactions, BFI Co., LLC indirectly holds 20,577 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the sales are pre-planned via a 10b5-1 plan, significant insider selling by a CEO and 10% owner can still be perceived as a negative signal by the market, even if it's for personal financial planning. The pre-planned nature mitigates the negativity somewhat, preventing a lower score.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an immediate reaction to new, undisclosed information.

Negatives

• Significant insider selling by a key executive and 10% owner could be perceived negatively by the market, potentially signaling a lack of confidence or a desire to diversify holdings.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Management Comments

• Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI.
• Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information directly related to broader industry trends or competitive landscape. Insider selling can sometimes be interpreted by the market as a signal, but when executed under a 10b5-1 plan, it often reflects personal financial planning rather than a change in company outlook.

Related Party Transactions

• Jack Bendheim, as a reporting person, director, and officer, exercises voting and dispositive power over BFI Co., LLC, which directly held and sold the reported securities. Mr. Bendheim disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the insider selling as a potential lack of confidence, which could lead to negative sentiment and potential downward pressure on the stock price.
• The sales were pre-planned, which generally reduces the immediate negative impact compared to unscheduled sales, as it suggests personal financial management rather than a reaction to adverse company news.

Next Steps

• The filing does not mention any specific future actions, events, or milestones beyond the completion of these transactions.

Key Dates

Recommendation

The insider selling by the CEO and 10% owner, while substantial in value, was conducted under a pre-arranged 10b5-1 trading plan. This suggests personal financial planning rather than a reaction to new, adverse company-specific information. Therefore, it does not necessarily indicate a fundamental deterioration in the company's prospects. Investors should 'hold' and monitor future company performance and additional insider activity rather than reacting solely to this scheduled transaction.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Selling, Form 4, 10b5-1 Plan, Stock Sale, CEO, Director, 10% Owner